Director Dennis Podlesak of Syndax Pharmaceuticals Inc filed a Form 4 on October 30, 2026, reporting the exercise of 8,000 stock options and the same-day sale of 8,000 shares of common stock on October 29, 2026, pursuant to a Rule 10b5-1 plan.

Key Highlights

  • Option exercise: Podlesak acquired 8,000 shares of common stock on October 29, 2026, via stock option exercise at a price of $11.81 per share.
  • Same-day sale: All 8,000 acquired shares were sold on October 29, 2026, at prices ranging from $14.00 to $14.59, with a reported weighted sale price of $14.2145.
  • 10b5-1 plan: According to the filing, the sales were effected pursuant to a Rule 10b5-1 plan "adopted by the Reporting Person solely covering equity grants with expiration dates prior to October 31, 2026."
  • Remaining ownership: Following the transactions, Podlesak directly holds 239,763 shares of common stock.
  • Options remaining: The filing states Podlesak holds 127,000 options to purchase shares of common stock that are "vested and immediately exercisable and no unvested options to purchase shares of common stock."
  • Expiring option: The exercised option, with an exercise price of $11.81, had an expiration date of October 31, 2026, and was fully vested.

Podlesak's October 29 Option Exercise and Share Sale at Syndax Pharmaceuticals

Dennis Podlesak, a director at Syndax Pharmaceuticals Inc (NASDAQ:SNDX), reported two transactions on October 29, 2026, in a Form 4 filed with the SEC on October 30, 2026. He first exercised stock options covering 8,000 shares of common stock at an exercise price of $11.81 per share, bringing his beneficial ownership to 247,763 shares at that point in the sequence.

Immediately following the exercise, Podlesak disposed of all 8,000 shares in an open-market sale. According to the filing, the sale price ranged from $14.00 to $14.59, with a weighted average reported as $14.2145. After the sale, his directly held common stock position stood at 239,763 shares. The filing notes the transactions were carried out under a Rule 10b5-1 plan that covered equity grants with expiration dates prior to October 31, 2026, the date on which the exercised option was set to expire.

The filing further discloses that following these transactions, Podlesak retains 127,000 options to purchase common stock, all of which are vested and immediately exercisable, with no unvested options remaining. The Form 4 was signed by Michael A. Metzger as Attorney-in-Fact on October 30, 2026.

What Was Disclosed

Director Dennis Podlesak reported the October 29, 2026, exercise of 8,000 stock options at $11.81 and the same-day sale of those shares at a weighted average of $14.2145, leaving him with 239,763 shares held directly and 127,000 vested options outstanding.